Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

This study uses a special PET scan with a radioactive tracer (68Ga-DOTATOC) to see if certain receptors found on tumors — called somatostatin receptors — are present in people with metastatic breast cancer. If so, this could open the door to new targeted treatments. Participants will get both a standard FDG-PET scan and this newer scan for comparison. **You may be eligible if...** - You are over 18 years old - You have metastatic breast cancer (cancer that has spread beyond the breast) - Your primary tumor is ER-positive and HER2-negative (a common hormone-driven subtype) - You have already completed at least one systemic treatment for metastatic disease - You have visible liver and bone metastases on standard imaging **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have poor kidney function - You have already received certain targeted therapies called PRRT - You are unable to have PET/CT scans Talk to your doctor to see if this trial is right for you.